Compare ANNX & IBCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANNX | IBCP |
|---|---|---|
| Founded | 2011 | 1864 |
| Country | United States | United States |
| Employees | N/A | 270 |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 873.3M | 776.0M |
| IPO Year | 2020 | 2010 |
| Metric | ANNX | IBCP |
|---|---|---|
| Price | $5.17 | $36.88 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 2 |
| Target Price | $16.50 | ★ $37.00 |
| AVG Volume (30 Days) | ★ 2.5M | 174.9K |
| Earning Date | 05-11-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 3.35% |
| EPS Growth | N/A | ★ 3.48 |
| EPS | N/A | ★ 1.72 |
| Revenue | N/A | ★ $32,075,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16,320.74 | $8.98 |
| P/E Ratio | ★ N/A | $21.48 |
| Revenue Growth | N/A | ★ 0.30 |
| 52 Week Low | $2.03 | $29.83 |
| 52 Week High | $7.18 | $39.24 |
| Indicator | ANNX | IBCP |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 42.60 |
| Support Level | N/A | $35.16 |
| Resistance Level | N/A | $37.37 |
| Average True Range (ATR) | 0.00 | 0.55 |
| MACD | 0.00 | -0.24 |
| Stochastic Oscillator | 0.00 | 0.00 |
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Independent Bank Corp. operates as a commercial bank. It offers a broad range of banking services to individuals and businesses, including checking and savings accounts, commercial lending, direct and indirect consumer financing, mortgage lending, and safe deposit box services. It also provides internet and mobile banking capabilities to its customers. The firm's principal markets are the rural and suburban communities across Lower Michigan. The firm generates the majority of its revenue from Interest and fees on loans.